These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35720246)

  • 1. Evaluation of the acid-neutralizing capacity and other properties of antacids marketed in Morocco.
    Yafout M; Elhorr H; Otmani ISE; Khayati Y
    Med Pharm Rep; 2022 Jan; 95(1):80-87. PubMed ID: 35720246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of buffering capacity and acid neutralizing-pH time profile of antacids.
    Lin MS; Sun P; Yu HY
    J Formos Med Assoc; 1998 Oct; 97(10):704-10. PubMed ID: 9830281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of antacid suspensions containing aluminum hydroxide and magnesium hydroxide.
    Hem SL; White JL; Buehler JD; Luber JR; Grim WM; Lipka EA
    Am J Hosp Pharm; 1982 Nov; 39(11):1925-30. PubMed ID: 7148862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing capacity and cost effectiveness of antacids.
    Drake D; Hollander D
    Ann Intern Med; 1981 Feb; 94(2):215-7. PubMed ID: 6781389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir.
    Krishna R; East L; Larson P; Valiathan C; Butterfield K; Teng Y; Hernandez-Illas M
    J Pharm Pharmacol; 2016 Nov; 68(11):1359-1365. PubMed ID: 27671833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invitro evaluation of the neutralising capacity of twenty brands of antacids in Lagos, Nigeria.
    Adepoju-Bello AA; Akpabio UE; Ayoola GA; Coker HA; Enwuru NV
    Nig Q J Hosp Med; 2008; 18(3):153-5. PubMed ID: 19062480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The neutralizing capacity and sodium content of antacid brands on the Kenyan market.
    Kibwage IO; Machine A; Hagos B; Hoogmartens J
    East Afr Med J; 1995 Mar; 72(3):194-7. PubMed ID: 7796775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of antacid compounds containing both aluminum and magnesium. II. Codried powders.
    Peterson CL; Perry DL; Masood H; White JL; Hem SL; Fritsch C; Haeusler F
    Pharm Res; 1993 Jul; 10(7):1005-7. PubMed ID: 8378241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Determination of formulation quantities for three kinds of antacid using triangle coordinates].
    Sofue M; Ueda Y; Yamamoto M; Yamasaki T; Manabe T
    Yakugaku Zasshi; 1997 Mar; 117(3):185-92. PubMed ID: 9109346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Food and Antacids on Pharmacokinetics and Pharmacodynamics of Lesinurad, a Selective Urate Reabsorption Inhibitor.
    Shen Z; Lee CA; Valdez S; Yang X; Wilson DM; Flanagan T; Gillen M
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):647-656. PubMed ID: 30748125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acid neutralization capacity of Canadian antacid formulations.
    MacCara ME; Nugent FJ; Garner JB
    Can Med Assoc J; 1985 Mar; 132(5):523-7. PubMed ID: 3971269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acid-neutralizing capacity and sodium content of antacid products from Belgium.
    Gombatz VW
    Clin Ther; 1984; 6(2):151-4. PubMed ID: 6705010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Determination of neutralization capacity of antacids in gastric juice].
    Halter F
    Z Gastroenterol; 1983 Mar; 21 Suppl():33-40. PubMed ID: 6858409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adsorption of bile acids by sucralfate, antacids, and cholestyramine in vitro.
    Ståhlberg M; Jalovaara P; Laitinen S; Mokka R; Hentilä R; Järvensivu P; Kairaluoma M
    Clin Ther; 1987; 9(6):615-21. PubMed ID: 3440273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology and clinical use of antacids.
    Green FW; Norton RA; Kaplan MM
    Am J Hosp Pharm; 1975 Apr; 32(4):425-9. PubMed ID: 236651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy with antacids].
    Holtermüller KH
    Fortschr Med; 1979 Jun; 97(23):1068-71, 1087. PubMed ID: 37146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of antacid compounds containing both aluminum and magnesium. I. Crystalline powders.
    Peterson CL; Perry DL; Masood H; Lin H; White JL; Hem SL; Fritsch C; Haeusler F
    Pharm Res; 1993 Jul; 10(7):998-1004. PubMed ID: 8378263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro evaluation of liquid antacid products.
    Sherrill MC; Rudd GD
    Am J Hosp Pharm; 1982 Feb; 39(2):300-2. PubMed ID: 7058802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of food on antacid neutralizing capacity in man.
    Halter F; Huber R; Häcki WH; Varga L; Bachmann C
    Eur J Clin Invest; 1982 Jun; 12(3):209-17. PubMed ID: 6809470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lattice structure antacids and antacid mixtures].
    Miederer SE; Schmidt C
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():130-5. PubMed ID: 3660893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.